Zdrowie i gospodarka · 26/12/2012

FDA Hosts Public Workshop on Minimal Residual Disease Biomarkers for Acute Myeloid Leukemia Treatment

The FDA, in partnership with the American Society of Clinical Oncology, is hosting a public workshop to discuss extending the use of minimal residual disease biomarkers in evaluating new treatments for acute myeloid leukemia, with a focus on identifying suitable surrogate endpoints and technical challenges.